SEEL (Seelos Therapeutics, Inc) Margin bathi reged

SEEL (Seelos Therapeutics Inc) - tandha merek perusahaan

Gross margin growth for Seelos Therapeutics (SEEL) correlates with the success of SLS-002 intranasal ketamine trials for suicidal ideation, with the current mark standing at 0.00. The financial model relies on grants and future sales of CNS drugs. The company's operations are strictly regulated by FDA standards regarding biomaterial disposal, ensuring a baseline environmental standard.

SEEL: Rentabilitas reged Seelos Therapeutics, Inc 04.07.2022 - 26.10.2024

Rincian metrik komprehensif lan analitis Seelos Therapeutics (SEEL)

Ringkesan analisis perusahaan:Seelos Therapeutics, Inc. - SEEL
Produk seri Seelos Therapeutics Inc

For Seelos Therapeutics (SEEL), which is currently in the clinical trial stage without commercial sales, the gross profit margin reflects a lack of operating income amid rising R&D costs. This indicator is calculated as the difference between revenue and cost of goods sold, expressed as a percentage of total turnover. The current value of 0.00 confirms a negative trend, indicating a high dependence of capital stability on external financing.